

# Jeffrey S Barrett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8347710/publications.pdf>

Version: 2024-02-01

49  
papers

1,966  
citations

361413

20  
h-index

243625

44  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2398  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of treatment regimen with moroctocog alfa (AFâ€CC) on bleeding rates in paediatric patients with severe haemophilia A. <i>Haemophilia</i> , 2020, 26, e232-e235.	2.1	0
2	Perspective on Dataâ€Sharing Requirements for the Necessary Evolution of Drug Development. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 688-690.	2.0	2
3	Realâ€World Data: An Unrealized Opportunity in Global Health?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 57-59.	4.7	7
4	A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2019, 6, 23-28.	0.6	1
5	Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AFâ€CC) in Subjects With Severe Hemophilia A. <i>Clinical and Translational Science</i> , 2018, 11, 283-288.	3.1	4
6	Clinical experience with moroctocog alfa (<sc>AF</sc>â€<sc>CC</sc>) in younger paediatric patients with severe haemophilia A: Two openâ€label studies. <i>Haemophilia</i> , 2018, 24, 604-610.	2.1	5
7	A Pilot Doseâ€Finding Study of Etanercept in Rheumatoid Arthritis. <i>Clinical and Translational Science</i> , 2018, 11, 38-45.	3.1	3
8	The Path to Perfect Pediatric Posology â€” Drug Development in Pediatrics. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S48-S57.	2.0	15
9	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 535-548.	2.3	50
10	Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 920-926.	1.6	4
11	Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 977-988.	4.7	20
12	An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A. <i>Clinical Therapeutics</i> , 2017, 39, 1313-1319.	2.5	4
13	Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1052-1057.	3.4	10
14	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017, 12, e0175207.	2.5	92
15	Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. <i>Clinical Therapeutics</i> , 2016, 38, 936-944.	2.5	7
16	Population pharmacokinetic modelling of factor <sc>IX</sc> activity after administration of recombinant factor <sc>IX</sc> in patients with haemophilia B. <i>Haemophilia</i> , 2016, 22, e359-66.	2.1	10
17	Onceâ€weekly prophylactic treatment vs. onâ€demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. <i>Haemophilia</i> , 2016, 22, 381-388.	2.1	41
18	Don't Do Different Thingsâ€   Do Things Differently! Drug Development in Rare Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 333-335.	4.7	2

#	ARTICLE	IF	CITATIONS
19	Industry Perspective of Drug Development for Pregnant/Breastfeeding Women. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 19-21.	4.7	1
20	Assessment of relative bioavailability of two presentations of moroctocog alfa (AFâ€CC) in subjects with moderately severe or severe hemophilia A. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 237-241.	1.6	5
21	Peptides, mAbs, bispecifics, oh my! clinical pharmacology challenges in the development of biologics. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S1-3.	2.0	1
22	Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. <i>Thrombosis and Haemostasis</i> , 2015, 114, 676-684.	3.4	9
23	Steadyâ€state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 235-241.	1.6	5
24	Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 151-157.	1.6	19
25	Comparative Bioavailability Study of Single-Dose Film-Coated and Sugar-Coated Ethionamide Tablets in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2014, 36, 982-987.	2.5	6
26	Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 70-74.	2.0	13
27	Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 513-519.	2.0	9
28	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 835-842.	1.9	9
29	Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1756-1762.	3.2	208
30	Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1065-1072.	3.2	89
31	Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 130-136.	3.2	44
32	Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1379-1387.	2.0	32
33	Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 32-37.	1.6	34
34	Comparative Sirolimus Pharmacokinetics After Single-Dose Administration of Two Prototype 0.5-mg Tablets in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 52-6.	1.6	1
35	Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 589-597.	1.9	4
36	Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial. <i>Transplantation</i> , 2011, 92, 303-310.	1.0	198

#	ARTICLE	IF	CITATIONS
37	Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 864-875.	2.0	17
38	Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5200-5204.	3.2	41
39	Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5180-5186.	3.2	35
40	Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4085-4089.	3.2	33
41	Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. <i>Haemophilia</i> , 2005, 11, 571-582.	2.1	60
42	Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2336-2347.	1.6	506
43	Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 543-550.	2.0	38
44	Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 873-880.	2.0	54
45	Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1244-1251.	2.0	34
46	Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1206-1214.	2.0	124
47	Evaluating Possible Pharmacokinetic Interactions between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients with Various Degrees of Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 979-986.	2.0	8
48	Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 729-737.	2.0	22
49	Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two-Stage Pharmacokinetic Analysis. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 610-617.	2.0	22